Ann Arbor Stage III Non-Hodgkin Lymphoma
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
4 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
Phase 1(1)
| Drug | Company |
|---|---|
| Veliparib | Filana Therapeutics Inc. (FLNA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Ann Arbor Stage III Non-Hodgkin Lymphoma?
BioSniper tracks 4 drugs in development for Ann Arbor Stage III Non-Hodgkin Lymphoma across 1 company.
How many clinical trials target Ann Arbor Stage III Non-Hodgkin Lymphoma?
There are 1 clinical trial targeting Ann Arbor Stage III Non-Hodgkin Lymphoma tracked by BioSniper.
What is the prevalence of Ann Arbor Stage III Non-Hodgkin Lymphoma?
The estimated prevalence of Ann Arbor Stage III Non-Hodgkin Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Ann Arbor Stage III Non-Hodgkin Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis